Clinical Trial Update: HIDIT II - PegIFN-alfa2a Plus Tenofovir in Chronic Delta Hepatitis [Phase 2]

View source ↗

Summary

Phase 2 trial update for HIDIT II evaluating PegIFN-alfa2a plus tenofovir in chronic hepatitis D has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis D

Drugs mentioned

• PegIFN-alfa2a (pegylated interferon alfa-2a)
• Tenofovir (Tenofovir)

Snippet

Sponsor: HepNet Study House, German Liverfoundation | Conditions: Hepatitis D | Phase 2 | Status: COMPLETED